{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:22:44Z","timestamp":1790738564254,"version":"4.1.0"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["1357-19"],"award-info":[{"award-number":["1357-19"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.blre.2023.101128","type":"journal-article","created":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T02:55:12Z","timestamp":1692413712000},"page":"101128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Classification, risk stratification and response assessment in myelodysplastic syndromes\/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)"],"prefix":"10.1016","volume":"62","author":[{"given":"Maximilian","family":"Stahl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Philipp","family":"Bewersdorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuoer","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo Giovanni Della","family":"Porta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Komrokji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina L.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Abdel-Wahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Steensma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel T.","family":"Starczynowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkael A.","family":"Sekeres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Sallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail J.","family":"Roboz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Padron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olatoyosi","family":"Odenike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Nimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Nazha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Majeti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Little","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan F.","family":"List","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Kon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Hourigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Hasserjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Halene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Figueroa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Efficace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy E.","family":"DeZern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naval G.","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane E.","family":"Churpek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hetty E.","family":"Carraway","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rena","family":"Buckstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Boultwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Borate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Bejar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H.","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Santini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Savona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Zeidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.blre.2023.101128_bb0005","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia."},{"issue":"11","key":"10.1016\/j.blre.2023.101128_bb0010","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.blre.2023.101128_bb0015","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1038\/s41375-022-01724-9","article-title":"Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the international workshop for myelodysplastic syndromes","volume":"36","author":"Zeidan","year":"2022","journal-title":"Leukemia."},{"issue":"7","key":"10.1016\/j.blre.2023.101128_bb0020","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evidence"},{"issue":"33","key":"10.1016\/j.blre.2023.101128_bb0025","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.20.02810","article-title":"Personalized prediction model to risk stratify patients with myelodysplastic syndromes","volume":"39","author":"Nazha","year":"2021","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.blre.2023.101128_bb0030","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the international working group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood."},{"issue":"17","key":"10.1016\/j.blre.2023.101128_bb0035","first-page":"2047","article-title":"Consensus proposal for revised international working group response criteria for higher risk myelodysplastic syndromes","volume":"141","author":"Zeidan","year":"2023","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.blre.2023.101128_bb0040","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2023.101128_bb0045","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2141.1982.tb08475.x","article-title":"Proposals for the classification of the myelodysplastic syndromes","volume":"51","author":"Bennett","year":"1982","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.blre.2023.101128_bb0050","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2023.101128_bb0055","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/MOH.0000000000000748","article-title":"The fifth edition of the World Health Organization classification and the international consensus classification of myeloid neoplasms: evolving guidelines in the molecular era with practical implications","volume":"30","author":"Zheng","year":"2023","journal-title":"Curr Opin Hematol"},{"issue":"11","key":"10.1016\/j.blre.2023.101128_bb0060","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.blre.2023.101128_bb0065","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood."},{"issue":"11","key":"10.1016\/j.blre.2023.101128_bb0070","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1200\/JCO.20.01659","article-title":"Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes","volume":"39","author":"Bersanelli","year":"2021","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.blre.2023.101128_bb0075","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/bloodadvances.2018019414","article-title":"The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort","volume":"2","author":"Stahl","year":"2018","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.blre.2023.101128_bb0080","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3343\/alm.2022.42.3.299","article-title":"Myelodysplastic syndromes with bone marrow fibrosis: an update","volume":"42","author":"Jain","year":"2022","journal-title":"Ann Lab Med"},{"issue":"3","key":"10.1016\/j.blre.2023.101128_bb0085","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2021011304","article-title":"Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal","volume":"139","author":"Estey","year":"2022","journal-title":"Blood."},{"issue":"5","key":"10.1016\/j.blre.2023.101128_bb0090","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1080\/10428194.2020.1861267","article-title":"Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia","volume":"62","author":"Chen","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"10.1016\/j.blre.2023.101128_bb0095","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.blre.2023.101128_bb0100","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood."},{"issue":"14","key":"10.1016\/j.blre.2023.101128_bb0105","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and Azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101128_bb0110","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1182\/blood-2021-145123","article-title":"CPX 351 as first line treatment in higher risk MDS. A phase II trial by the GFM","volume":"138","author":"Peterlin","year":"2021","journal-title":"Blood."},{"issue":"Supplement 1","key":"10.1016\/j.blre.2023.101128_bb0115","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood-2020-139492","article-title":"Safety, efficacy, and patient-reported outcomes of venetoclax in combination with azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome: a phase 1b study","volume":"136","author":"Garcia","year":"2020","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101128_bb0120","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.blre.2023.101128_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.blre.2018.09.001","article-title":"Epidemiology of myelodysplastic syndromes: why characterizing the beast is a prerequisite to taming it","volume":"34","author":"Zeidan","year":"2019","journal-title":"Blood Rev"},{"issue":"4","key":"10.1016\/j.blre.2023.101128_bb0130","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.blre.2023.101128_bb0135","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood."},{"issue":"7","key":"10.1016\/j.blre.2023.101128_bb0140","doi-asserted-by":"crossref","first-page":"e521","DOI":"10.1016\/S2352-3026(23)00090-X","article-title":"CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 study","volume":"10","author":"Peterlin","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2023.101128_bb0145","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1182\/blood-2021-145123","article-title":"CPX 351 as first line treatment in higher risk MDS. A phase II trial by the GFM. ASH annual meeting","author":"Peterlin","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.blre.2023.101128_bb0150","series-title":"A product of \u201cclash of titans\u201d or true reflection of disease biology? Validation of 2022 WHO and ICC classifications in a large dataset of patients with myelodysplastic syndrome","author":"Ball","year":"2022"},{"issue":"5","key":"10.1016\/j.blre.2023.101128_bb0155","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","article-title":"A revised European-American classification of lymphoid neoplasms: a proposal from the international lymphoma study group","volume":"84","author":"Harris","year":"1994","journal-title":"Blood."},{"key":"10.1016\/j.blre.2023.101128_bb0160","series-title":"Message from the president to members of the Society for Hematopathology","author":"Hasserjian","year":"2023"},{"key":"10.1016\/j.blre.2023.101128_bb0165","series-title":"community PsMfDRHfaith","year":"2023"},{"key":"10.1016\/j.blre.2023.101128_bb0170","doi-asserted-by":"crossref","first-page":"101033","DOI":"10.1016\/j.blre.2022.101033","article-title":"Prognostication in myelodysplastic syndromes (neoplasms): molecular risk stratification finally coming of age","volume":"59","author":"Xie","year":"2022","journal-title":"Blood Rev"},{"issue":"6","key":"10.1016\/j.blre.2023.101128_bb0175","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood."},{"issue":"23","key":"10.1016\/j.blre.2023.101128_bb0180","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1200\/JCO.2006.08.5696","article-title":"Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes","volume":"25","author":"Malcovati","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2023.101128_bb0185","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/cncr.23697","article-title":"Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original international prognostic scoring system","volume":"113","author":"Kantarjian","year":"2008","journal-title":"Cancer."},{"issue":"3","key":"10.1016\/j.blre.2023.101128_bb0190","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/sj.leu.2405070","article-title":"A prognostic score for patients with lower risk myelodysplastic syndrome","volume":"22","author":"Garcia-Manero","year":"2008","journal-title":"Leukemia."},{"issue":"7","key":"10.1016\/j.blre.2023.101128_bb0195","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/ajh.23454","article-title":"Validation of the revised international prognostic scoring system in treated patients with myelodysplastic syndromes","volume":"88","author":"Mishra","year":"2013","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.blre.2023.101128_bb0200","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/bmt.2017.171","article-title":"Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome\/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party","volume":"52","author":"Scheid","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"22","key":"10.1016\/j.blre.2023.101128_bb0205","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2023.101128_bb0210","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia."},{"issue":"26","key":"10.1016\/j.blre.2023.101128_bb0215","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.blre.2023.101128_bb0220","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/leu.2015.304","article-title":"Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes","volume":"30","author":"Sallman","year":"2016","journal-title":"Leukemia."},{"issue":"10","key":"10.1016\/j.blre.2023.101128_bb0225","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.blre.2023.101128_bb0230","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.blre.2023.101128_bb0235","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1038\/leu.2016.138","article-title":"Incorporation of molecular data into the revised international prognostic scoring system in treated patients with myelodysplastic syndromes","volume":"30","author":"Nazha","year":"2016","journal-title":"Leukemia."},{"issue":"12","key":"10.1016\/j.blre.2023.101128_bb0240","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1038\/leu.2017.266","article-title":"Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes","volume":"31","author":"Nazha","year":"2017","journal-title":"Leukemia."},{"issue":"7","key":"10.1016\/j.blre.2023.101128_bb0245","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","volume":"1","author":"Bernard","year":"2022","journal-title":"NEJM Evidence"},{"issue":"3","key":"10.1016\/j.blre.2023.101128_bb0250","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.blre.2023.101128_bb0255","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1038\/leu.2017.88","article-title":"Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised international prognostic scoring system","volume":"31","author":"Della Porta","year":"2017","journal-title":"Leukemia."},{"key":"10.1016\/j.blre.2023.101128_bb0260","series-title":"MYELODYSPLASTIC NEOPLASMS (MDS) CLASSIFICATION FROM WHO 2017 TO WHO 2022 AND ICC 2022: AN EXPANDED ANALYSIS OF 7017 PATIENTS ON BEHALF OF THE INTERNATIONAL CONSORTIUM FOR MDS (ICMDS). EHA Meeting","author":"Rami","year":"2023"},{"issue":"3","key":"10.1016\/j.blre.2023.101128_bb0265","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/PPO.0000000000000666","article-title":"Evolution of therapeutic benefit measurement criteria in myelodysplastic syndromes\/neoplasms","volume":"29","author":"Stempel","year":"2023","journal-title":"Cancer J"},{"issue":"10","key":"10.1016\/j.blre.2023.101128_bb0270","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1182\/blood-2018-06-857102","article-title":"Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials","volume":"133","author":"Platzbecker","year":"2019","journal-title":"Blood."},{"issue":"21","key":"10.1016\/j.blre.2023.101128_bb0275","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1182\/blood-2013-02-453068","article-title":"How we treat lower-risk myelodysplastic syndromes","volume":"121","author":"Fenaux","year":"2013","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2023.101128_bb0280","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.blre.2023.101128_bb0285","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/leu.2015.296","article-title":"Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion","volume":"30","author":"Toma","year":"2016","journal-title":"Leukemia."},{"issue":"9","key":"10.1016\/j.blre.2023.101128_bb0290","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1038\/leu.2017.192","article-title":"A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes","volume":"31","author":"Platzbecker","year":"2017","journal-title":"Leukemia."},{"issue":"6","key":"10.1016\/j.blre.2023.101128_bb0295","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1046\/j.1365-2141.2003.04153.x","article-title":"A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life","volume":"120","author":"Hellstrom-Lindberg","year":"2003","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.blre.2023.101128_bb0300","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1038\/s41375-018-0118-9","article-title":"A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-alpha in anemic patients with low-risk MDS","volume":"32","author":"Fenaux","year":"2018","journal-title":"Leukemia."},{"issue":"2","key":"10.1016\/j.blre.2023.101128_bb0305","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.blre.2023.101128_bb0310","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1182\/blood-2018-06-857102","article-title":"Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials","volume":"133","author":"Platzbecker","year":"2019","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2023.101128_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2022.101405","article-title":"How can we improve response assessments in MDS? Strategies to improve response assessment in MDS treatment paradigms","volume":"35","author":"Bejar","year":"2022","journal-title":"Best Pract Res Clin Haematol"},{"issue":"10399","key":"10.1016\/j.blre.2023.101128_bb0320","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0140-6736(23)00874-7","article-title":"Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial","volume":"402","author":"Platzbecker","year":"2023","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.blre.2023.101128_bb0325","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1182\/bloodadvances.2022009564","article-title":"Post-azacitidine clone size predicts outcome of patients with myelodysplastic syndromes and related myeloid neoplasms","volume":"7","author":"Nannya","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2023.101128_bb0330","series-title":"Myelodysplastic Syndromes Version 1","author":"National Comprehensive Cancer Network Practice Guidelines in Oncology","year":"2023"},{"issue":"12","key":"10.1016\/j.blre.2023.101128_bb0335","first-page":"3671","article-title":"Report of an international working group to standardize response criteria for myelodysplastic syndromes","volume":"96","author":"Cheson","year":"2000","journal-title":"Blood."},{"issue":"24","key":"10.1016\/j.blre.2023.101128_bb0340","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.2015.66.2510","article-title":"Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: north American intergroup study SWOG S1117","volume":"35","author":"Sekeres","year":"2017","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.blre.2023.101128_bb0345","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1182\/bloodadvances.2022007334","article-title":"Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS\/chronic myelomonocytic leukemia or low-blast-percentage AML","volume":"6","author":"Ad\u00e8s","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.blre.2023.101128_bb0350","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/cam4.3608","article-title":"Validation of international working group response criteria in higher-risk myelodysplastic syndromes: a report on behalf of the MDS clinical research Consortium","volume":"10","author":"Komrokji","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.blre.2023.101128_bb0355","first-page":"2604","article-title":"Response rate, event-free survival (EFS) and overall survival (OS) in higher-risk myelodysplastic syndromes (HR-MDS): U.S. food and drug administration (FDA) patient-level analyses","author":"Kim","year":"2021","journal-title":"ASH Ann Meet: Blood"},{"issue":"4","key":"10.1016\/j.blre.2023.101128_bb0360","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2023.101128_bb0365","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ajh.24252","article-title":"Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)","volume":"91","author":"DiNardo","year":"2016","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.blre.2023.101128_bb0370","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1182\/blood.2021011304","article-title":"Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal","volume":"139","author":"Estey","year":"2022","journal-title":"Blood."},{"issue":"11","key":"10.1016\/j.blre.2023.101128_bb0375","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood."},{"issue":"11","key":"10.1016\/j.blre.2023.101128_bb0380","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41408-022-00748-9","article-title":"Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS)","volume":"12","author":"Brunner","year":"2022","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.blre.2023.101128_bb0385","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.blre.2023.101128_bb0390","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1002\/cncr.30903","article-title":"A call for action: increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials","volume":"123","author":"Zeidan","year":"2017","journal-title":"Cancer."},{"issue":"36","key":"10.1016\/j.blre.2023.101128_bb0395","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.2217\/fon-2021-0936","article-title":"Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?","volume":"17","author":"Zeidan","year":"2021","journal-title":"Future Oncol"},{"issue":"15","key":"10.1016\/j.blre.2023.101128_bb0400","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1200\/JCO.2010.30.9245","volume":"29","author":"Lubbert","year":"2011","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.blre.2023.101128_bb0405","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1182\/bloodadvances.2022007334","article-title":"Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS\/chronic myelomonocytic leukemia or low-blast-percentage AML","volume":"6","author":"Ades","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.blre.2023.101128_bb0410","series-title":"Adult patients with higher-risk myelodysplastic syndromes (MDS)","article-title":"Primary results of Stimulus-MDS1: A randomized, double-blind, placebo-controlled phase II study of TIM-3 inhibition with Sabatolimab added to hypomethylating agents (HMAs)","author":"AZe","year":"2022"},{"issue":"6","key":"10.1016\/j.blre.2023.101128_bb0415","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1001\/jamaoncol.2017.5618","article-title":"A 25-year experience of US Food and Drug Administration accelerated approval of malignant hematology and oncology drugs and biologics","volume":"4","author":"Beaver","year":"2018","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.blre.2023.101128_bb0420","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1038\/s41375-021-01125-4","article-title":"Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS\/CMML or low-blast AML","volume":"35","author":"Sekeres","year":"2021","journal-title":"Leukemia."},{"issue":"3","key":"10.1016\/j.blre.2023.101128_bb0425","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/s41375-018-0367-7","article-title":"Rethinking clinical trial endpoints in myelodysplastic syndromes","volume":"33","author":"Sekeres","year":"2019","journal-title":"Leukemia."},{"issue":"3","key":"10.1016\/j.blre.2023.101128_bb0430","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood-2013-11-540021","article-title":"Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life","volume":"123","author":"Abel","year":"2014","journal-title":"Blood."},{"issue":"6","key":"10.1016\/j.blre.2023.101128_bb0435","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3324\/haematol.2015.140335","article-title":"Prospective international validation of the quality of life in myelodysplasia scale (QUALMS)","volume":"101","author":"Abel","year":"2016","journal-title":"Haematologica."},{"key":"10.1016\/j.blre.2023.101128_bb0440","article-title":"Development and validation of QOL-E\u00a9 instrument for the assessment of health-related quality of life in myelodysplastic syndromes","volume":"8","author":"Oliva","year":"2013","journal-title":"Central Eur J Med"},{"issue":"2","key":"10.1016\/j.blre.2023.101128_bb0445","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1016\/S1470-2045(22)00654-4","article-title":"Recommendations on the use of item libraries for patient-reported outcome measurement in oncology trials: findings from an international, multidisciplinary working group","volume":"24","author":"Piccinin","year":"2023","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.blre.2023.101128_bb0450","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/S1470-2045(15)00206-5","article-title":"Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study","volume":"16","author":"Efficace","year":"2015","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.blre.2023.101128_bb0455","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1002\/cncr.31193","article-title":"Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: an international study in patients with myelodysplastic syndromes","volume":"124","author":"Efficace","year":"2018","journal-title":"Cancer."},{"issue":"2","key":"10.1016\/j.blre.2023.101128_bb0460","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/bjh.17537","article-title":"Patient-reported fatigue refines prognosis in higher-risk myelodysplastic syndromes (MDS): a MDS-CAN study","volume":"194","author":"Amitai","year":"2021","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.blre.2023.101128_bb0465","doi-asserted-by":"crossref","first-page":"e267","DOI":"10.1016\/S1470-2045(18)30097-4","article-title":"Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada","volume":"19","author":"Kluetz","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.blre.2023.101128_bb0470","article-title":"Current landscape of translational and clinical research in myelodysplastic syndromes\/neoplasms (MDS): proceedings from the 1(st) International Workshop on MDS (iwMDS) of the International Consortium for MDS (icMDS)","volume":"101072","author":"Bewersdorf","year":"2023","journal-title":"Blood Rev"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X23000899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:32:50Z","timestamp":1759437170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X23000899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":94,"alternative-id":["S0268960X23000899"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2023.101128","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Classification, risk stratification and response assessment in myelodysplastic syndromes\/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2023.101128","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101128"}}